更新于：2024-07-01
GRO beta
更新于：2024-07-01
概要
基本信息
非在研机构  Ensoma, Inc.初创企业 |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
关联
5
项与 GRO beta 相关的临床试验A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of MGTA-145 in Combination With Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients With Sickle Cell Disease
A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination With Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Phase II Study of MGTA-145 in Combination With Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Patients With Multiple Myeloma
100 项与 GRO beta 相关的临床结果
登录后查看更多信息
100 项与 GRO beta 相关的转化医学
登录后查看更多信息
100 项与 GRO beta 相关的专利（医药）
登录后查看更多信息
34
项与 GRO beta 相关的文献（医药）2024-03-01Archives of biochemistry and biophysics
A multifactorial study of in situ antioxidant activity of modified GrO in myocardial reperfusion injury using the Langerdorff model
Article
作者: Goshovska, Yulia V ; Zhuravskyi, Sergey V ; Korkach, Yulia P ; Mys, Lidia A ; Kolev, Hristo ; Sencha-Hlevatska, Kateryna V ; Sementsov, Yury I ; Sagach, Vadym F
Carbon nanomaterials possess antioxidant properties that can be applied in biomedicine and clinics for the development of new highly effective treatments against oxidative stress-induced diseases like ischemic heart disease. We previously reported the usage of graphene oxide (GrO) as a precursor for the elaboration of such prototypes. The promising findings led to the development of two new modifications of GrO: nitrogen-doped (N-GrO) and l-cysteine functionalized (S-GrO) derivatives as possible antioxidant agents in ischemia-reperfusion (I/R) conditions. In this study, the cardioprotective and antioxidant potential of modified GrO as a pre-treatment in rats was evaluated for the first time. In Langendorff isolated rat heart I/R model, the left ventricle developed pressure (LVDP), the end-diastolic pressure (EDP), the maximal (dP/dtmax) and minimal (dP/dtmin) value of the first derivative of LVDP, and heart rate (HR) were measured. The oxidative-nitrosative markers, in particular, the rate of O2*- and H2O2 generation, the content of malonic dialdehyde, diene conjugates, and leukotriene as well as cNOS and iNOS activity were estimated. Obtained results show a significant restoration of cadiodynamic parameters at the reperfusion period. Simultaneously, all samples significantly reduced the rate of reactive oxygen species (ROS) and lipid peroxidation markers in cardiac homogenates and preserved cNOS activity at the preischemic level. This evidence makes GrO derivatives promising candidates for the correction of reperfusion disorders affecting myocardial function.
2023-04-11ACS omega
Tailoring Deep Eutectic Solvents to Provoke Solubility and Bioavailability of Naringin: Implications of a Computational Approach.
Article
作者: Dangre, Pankaj V ; Borkar, Maheshkumar R ; Pethe, Anil M ; Borikar, Sachin P ; Korekar, Pawan P ; Chaturvedi, Kaushalendra K
Recently, the applications of deep eutectic solvents (DESs) as green and sustainable solvents for the solubilization of functional foods and phytophenols have dramatically risen concerning global issues on the utilization of organic solvents. Nevertheless, developing a suitable DES system for phytocomponents to enhance its solubility and bioavailability is complex and requires a sound experimental setup. Herein, we have attempted to develop DES encompassing the choline chloride (ChCl) along with oxalic acid (OA), l-glutamine (l-Glu), urea (U), and glycerol (Gro) at different ratios to elicit the solubility and bioavailability of naringin (NAR). Several DES systems were designed and tested for solubility, kinematic viscosity, and pH. Among these, DES-NAR encompassing ChCl/Gro in a 1:3 ratio exhibited the maximum solubility of NAR (232.56 ± 7.1 mg/mL) and neutral characteristic and thus considered suitable for NAR. Further, the conductor-like screening model for real solvents (COSMO-RS) has been employed to estimate the molecular and electrostatic interactions. DES-NAR was evaluated by polarized optical microscopy, Fourier-transform infrared (FTIR), differential scanning calorimetry (DSC), and 1H NMR to investigate the molecular transition and interaction. Further, diffusion and permeability studies were performed, which suggest significant improvements in DES-NAR. Likewise, the pharmacokinetic studies revealed a two times increase in the oral bioavailability of NAR in a designed DES system. Thus, the work represents a systematic and efficient development of the DES system for a potential phytocomponent considering the biosafety impact, which may widen the interest in pharmaceutical and food sciences.
2022-04-03Free radical research
Graphene oxide nanoflakes prevent reperfusion injury of Langendorff isolated rat heart providing antioxidative activity in situ
Article
作者: Sementsov, Yury I. ; Korkach, Yulia P. ; Mys, Lida A. ; Voitko, Kateryna V. ; Zhuravskyi, Sergey V. ; Goshovska, Yulia V. ; Kolev, Hristo ; Demianenko, Eugeniy M. ; Sagach, Vadym F.
Carbon materials possess powerful antioxidant activity that might be promising for the development of new generation treatment of cardiovascular diseases, ischemic conditions, and reperfusion injury. The present study aimed to characterize the structure of nanosized graphene oxide (GrO) sample and evaluate the antioxidant efficacy of GrO in situ models of oxidative stress widely used in pre-clinical studies. The structure and surface chemistry of the initial samples were analyzed via LDS, RAMAN, LDI, TPD-MS, and FTIR methods. The GrO showed a strong ability to scavenge DPPH, hydroxyl, and superoxide anion free radicals and have a total antioxidant capacity. The DFT quantum-chemical calculation demonstrated the radical scavenging effect of GrO proceeding due to the physical adsorption of the free radical on the surface. For evaluation of the antioxidant effect of GrO in situ, we used the model of ischemia-reperfusion (I/R) of Langendorff isolated rat heart. We revealed that intravenous pretreatment of Wistar male rats with GrO significantly increased resistance of myocardium to I/R, improved restoration of heart function, prevented non-effective oxygen utilization, and I/R-induced reactive oxygen species production in cardiac tissue. Thus, our data demonstrate the perspective of further use of GrO for the development of antiischemic therapy.
6
项与 GRO beta 相关的新闻（医药）2023-06-29
·药时代
并购IPO临床2期临床3期
2023-02-06
·药时代
抗体药物偶联物临床2期临床申请临床1期细胞疗法
2023-02-03
临床2期财报细胞疗法抗体药物偶联物临床1期
100 项与 GRO beta 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镰状细胞血症 | 临床2期 | 美国 | Ensoma, Inc.初创企业 | 2022-06-24 |
| 急性淋巴细胞白血病 | 临床2期 | 美国 | Ensoma, Inc.初创企业 | 2021-06-16 |
| 急性髓性白血病 | 临床2期 | 美国 | Ensoma, Inc.初创企业 | 2021-06-16 |
| 骨髓增生异常综合征 | 临床2期 | 美国 | Ensoma, Inc.初创企业 | 2021-06-16 |
| 多发性骨髓瘤 | 临床2期 | 美国 | - | 2020-10-05 |
| 干细胞动员 | 临床2期 | 美国 | 2020-09-14 | |
| 造血干细胞移植 | 临床1期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 25 | 淵廠鹹網製淵淵簾選鹹(鏇艱糧積廠製網醖範願) = 鹽鏇膚遞鹹蓋醖襯製範 壓夢網鹽築齋鹹製選壓 (餘網鏇衊鑰鹽艱鹽鹽構, 廠淵積簾鹽顧廠鬱築襯 ~ 鏇醖憲夢繭窪齋鑰醖範) 更多 | - | 2022-09-10 | |||
临床2期 | - | Plerixafor+Mgta-145 | 製遞構窪繭壓壓膚鬱構(餘獵廠壓衊淵簾繭壓鏇) = 5.0 cells/kg x 10 6 繭繭憲鹽製齋築繭蓋製 (齋範鏇鬱鹽獵獵醖網範 ) | 积极 | 2021-11-05 | ||
临床2期 | 25 | 製憲鬱構蓋餘簾構餘齋(膚淵膚餘淵積鬱選蓋繭) = At least 1 adverse event (AE) was seen in 90% of patients, 20% had grade 2 AEs (anemia, hypokalemia) and 20% had grade 3 AEs (worsening of baseline grade 3 anemia; hypocalcemia); all resolved. Acute & transient bone pain was seen in 40% of patients (back-2, hip-1, sternum-1), all grade 1, all on day 1, & resolved without intervention after 6 minutes (3-10) 構範顧夢範築夢夢糧醖 (餘窪夢淵獵選醖築襯艱 ) | 积极 | 2021-05-28 | |||
临床1期 | - | - | 範鏇糧構範製鑰淵襯選(製餘鹹齋窪憲範壓窪窪) = 鏇鬱窪衊鹹齋遞製顧網 鏇網壓願淵簾憲蓋窪積 (範餘範襯廠鏇憲襯壓選 ) | - | 2021-03-14 | ||
临床1期 | CXCR2 | MMP-9 | TIMP-1 | - | 窪繭夢遞廠鏇顧顧觸願(築衊壓範齋製壓襯願鑰) = MGTA-145 monotherapy was well tolerated with no significant adverse events (AEs). Grade 1, transient lower back pain that dissipated within minutes was reported. The combination of MGTA-145 with plerixafor was well tolerated, with some subjects experiencing grade 1/2 gastrointestinal AEs commonly observed with plerixafor and one grade 2 back pain with MGTA-145 at 0.075 mg/kg that resolved within minutes. 鬱壓顧鬱廠齋鏇鏇襯衊 (齋鬱鑰鏇餘鹹鬱網淵顧 ) 更多 | 积极 | 2020-11-06 | ||
临床1期 | 一线 | - | 積醖構範艱膚淵齋鬱構(糧糧網蓋廠簾醖餘窪憲) = MGTA-145 monotherapy was well tolerated with no significant adverse events (AEs). Grade 1, transient lower back pain that dissipated within minutes was reported. The combination of MGTA-145 with plerixafor was well tolerated, with some subjects experiencing grade 1/2 gastrointestinal AEs commonly observed with plerixafor and one grade 2 back pain with MGTA-145 at 0.075 mg/kg that resolved within minutes. 願積壓艱築積繭鏇選願 (鹽膚衊餘蓋艱選衊簾窪 ) | 积极 | 2020-08-29 | ||
临床1期 | 一线 | - | 壓簾範簾蓋鹹顧餘範餘(憲遞選餘窪衊蓋壓鏇構) = some subjects experiencing grade 1/2 gastrointestinal AEs commonly observed with plerixafor and one grade 2 back pain with MGTA-145 at 0.075 mg/kg that resolved within minutes 衊齋簾製選壓繭顧廠衊 (願鹹齋淵遞襯壓壓餘築 ) 更多 | - | 2020-06-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用